上海莱士:SR604注射液进入Ⅲ期临床试验

智通财经
Yesterday
【上海莱士:SR604注射液进入Ⅲ期临床试验】上海莱士公告,公司在研产品SR604注射液“血友病A/B”适应症Ⅰ/Ⅱ期临床研究达到预设主要终点;近日,国家药品监督管理局药物临床试验登记与信息公示平台公示其Ⅲ期临床试验登记信息,试验登记号CTR20263539,拟进行0.4mg/kg每4周给药1次的多次给药试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10